Dec 2023 $4 M No. 6 $2 to $10 million 14
Zurex Pharma, Inc.: Raise no. 6, Dec 2023 × Investors in this round 14 investors had bought by the notice of Dec 29, 2023: 14 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $4 M of $4 M offered; $0 M still to sell
Smallest investment taken $50,000
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Wisconsin People named in the notice Alexander M Kasper · Executive Officer, Director Frederick A. Robertson · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Alexander M. Kasper, Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 29, 2023. Read the notice at the SEC .
equity SEC Jun 2020 $8 M No. 5 $2 to $10 million 18
Zurex Pharma, Inc.: Raise no. 5, Jun 2020 × Investors in this round 18 investors had bought by the notice of Jun 16, 2020: 18 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $8 M of $15 M offered; $8 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Wisconsin People named in the notice Alexander M Kasper · Executive Officer Carmine J Durham · Executive Officer, Director Roy Andrew Morgan · Executive Officer Frederick A. Robertson · Director Michael J. Liang · Director Robert Andrew Truitt · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Carmine J. Durham, Chief Executive Officer. Source: SEC Form D, newest notice filed Jun 16, 2020. Read the notice at the SEC .
equity SEC May 2018 $2 M No. 4 $2 to $10 million 11
Zurex Pharma, Inc.: Raise no. 4, May 2018 × Investors in this round 11 investors had bought by the notice of Jun 11, 2018: 11 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $2 M of $3 M offered; $1 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Wisconsin People named in the notice Alexander M. Kasper · Executive Officer Andrew M. Morgan · Executive Officer Carmine J. Durham · Executive Officer, Director Frederick A. Robertson · Director Michael J. Liang · Director Robert B. Truitt · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Carmine J. Durham, President and CEO. Source: SEC Form D, newest notice filed Jun 11, 2018. Read the notice at the SEC .
equity SEC Aug 2016 $6 M No. 3 $2 to $10 million 26
Zurex Pharma, Inc.: Raise no. 3, Aug 2016 × Investors in this round 26 investors had bought by the notice of Aug 11, 2016: 26 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $6 M of $8 M offered; $2 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Wisconsin People named in the notice Alexander M. Kasper · Executive Officer Andrew M. Morgan · Executive Officer Carmine J. Durham · Executive Officer, Director Frederick A. Robertson · Director Michael J. Liang · Director Robert B. Truitt · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Carmine J. Durham, President and CEO. Source: SEC Form D, newest notice filed Aug 11, 2016. Read the notice at the SEC .
equity SEC Jun 2014 $4 M No. 2 $2 to $10 million 13
Zurex Pharma, Inc.: Raise no. 2, Jun 2014 × Investors in this round 13 investors had bought by the notice of Jul 1, 2014: 13 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $4 M of $5 M offered; $1 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Wisconsin People named in the notice Alexander M. Kasper · Executive Officer Carmine J. Durham · Executive Officer, Director Frederick A. Robertson · Executive Officer, Director Roy A. Morgan · Executive Officer Connie A. Curran · Director Michael A. Liang · Director Robert B. Truitt · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Carmine J. Durham, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 1, 2014. Read the notice at the SEC .
equity SEC May 2012 $6 M No. 1 $2 to $10 million 11
Zurex Pharma, Inc.: Raise no. 1, May 2012 × Investors in this round 11 investors had bought by the notice of Jun 7, 2012: 11 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $6 M of $6 M offered
Smallest investment taken no minimum stated
What was sold equity
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Wisconsin People named in the notice Carmine J Durham · Executive Officer, Director R Andrew Morgan · Executive Officer Robert B Truitt · Executive Officer, Director Gary J Lehman · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Matthew L. Storms, Attorney for Zurex Pharma. Source: SEC Form D, newest notice filed Jun 7, 2012. Read the notice at the SEC .
equity SEC